003020 立方制药
已收盘 11-13 15:00:00
资讯
新帖
简况
立方制药(003020.SZ)子公司取得加替沙星滴眼液药品注册证书
智通财经 · 11-06
立方制药(003020.SZ)子公司取得加替沙星滴眼液药品注册证书
立方制药(003020.SZ)发布前三季度业绩,归母净利润1.09亿元,同比下降9.86%
智通财经 · 10-29
立方制药(003020.SZ)发布前三季度业绩,归母净利润1.09亿元,同比下降9.86%
立方制药(003020)9月30日股东户数2.06万户,较上期增加36%
证券之星 · 10-29
立方制药(003020)9月30日股东户数2.06万户,较上期增加36%
股市必读:立方制药新发布《关于收到原料药上市申请受理通知书的公告》
证券之星 · 10-16
股市必读:立方制药新发布《关于收到原料药上市申请受理通知书的公告》
立方制药(003020)10月15日主力资金净卖出49.87万元
证券之星 · 10-15
立方制药(003020)10月15日主力资金净卖出49.87万元
立方制药(003020)披露收到盐酸米安色林原料药上市申请受理通知书,10月14日股价下跌1.74%
证券之星 · 10-14
立方制药(003020)披露收到盐酸米安色林原料药上市申请受理通知书,10月14日股价下跌1.74%
立方制药(003020.SZ):盐酸氯普鲁卡因原料药上市申请获得批准
智通财经 · 10-13
立方制药(003020.SZ):盐酸氯普鲁卡因原料药上市申请获得批准
立方制药(003020)9月24日主力资金净买入123.50万元
证券之星 · 09-24
立方制药(003020)9月24日主力资金净买入123.50万元
股市必读:立方制药新发布《关于立方制药2026年第一次临时股东会的法律意见书》
证券之星 · 09-24
股市必读:立方制药新发布《关于立方制药2026年第一次临时股东会的法律意见书》
股市必读:立方制药新发布《关于参加2026年安徽上市公司投资者网上集体接待日活动的公告》
证券之星 · 09-11
股市必读:立方制药新发布《关于参加2026年安徽上市公司投资者网上集体接待日活动的公告》
股市必读:立方制药中报 - 第二季度单季净利润同比增长1.80%
证券之星 · 08-31
股市必读:立方制药中报 - 第二季度单季净利润同比增长1.80%
立方制药(003020)2026年中报简析:净利润同比下降2.24%
证券之星 · 08-30
立方制药(003020)2026年中报简析:净利润同比下降2.24%
立方制药(003020)披露关于调剂银行授信额度暨为子公司提供担保的进展公告,8月28日股价下跌0.53%
证券之星 · 08-28
立方制药(003020)披露关于调剂银行授信额度暨为子公司提供担保的进展公告,8月28日股价下跌0.53%
图解立方制药中报:第二季度单季净利润同比增长1.80%
证券之星 · 08-28
图解立方制药中报:第二季度单季净利润同比增长1.80%
立方制药(003020.SZ)发布半年度业绩,归母净利润8820.51万元,同比下降2.24%
智通财经 · 08-28
立方制药(003020.SZ)发布半年度业绩,归母净利润8820.51万元,同比下降2.24%
立方制药(003020)6月30日股东户数1.52万户,较上期减少8.82%
证券之星 · 08-28
立方制药(003020)6月30日股东户数1.52万户,较上期减少8.82%
立方制药(003020)披露收到盐酸曲唑酮原料药上市申请受理通知书,8月25日股价上涨6.63%
证券之星 · 08-25
立方制药(003020)披露收到盐酸曲唑酮原料药上市申请受理通知书,8月25日股价上涨6.63%
立方制药(003020)披露产品中选第12批国家药品集采,8月7日股价上涨5.13%
证券之星 · 08-07
立方制药(003020)披露产品中选第12批国家药品集采,8月7日股价上涨5.13%
股市必读:立方制药新发布《关于公司产品拟中选国家组织药品集中带量采购的公告》
证券之星 · 08-04
股市必读:立方制药新发布《关于公司产品拟中选国家组织药品集中带量采购的公告》
立方制药(003020.SZ):两款产品拟中选国家组织药品集中带量采购
智通财经 · 08-03
立方制药(003020.SZ):两款产品拟中选国家组织药品集中带量采购
加载更多
公司概况
公司名称:
合肥立方制药股份有限公司
所属行业:
批发业
上市日期:
2020-12-15
主营业务:
合肥立方制药股份有限公司的主营业务是药品制剂及原料药的研发、生产、销售,药品与医疗器械的批发、零售。公司的主要产品是精神麻醉药、独家现代中药。公司两次荣获“中国医药工业最具投资价值企业”称号,连续八年入选“中国化学制药工业企业综合实力百强”,获国家高新技术企业、安徽省专精特新企业50强、安徽省科学技术奖一等奖、皖美品牌示范企业等荣誉。
发行价格:
23.13
{"stockData":{"symbol":"003020","market":"SZ","secType":"STK","nameCN":"立方制药","latestPrice":14.87,"timestamp":1794553389000,"preClose":15.12,"halted":0,"volume":1779860,"delay":0,"changeRate":-0.0165,"floatShares":169000000,"shares":227999999,"eps":0.6716,"marketStatus":"已收盘","change":-0.25,"latestTime":"11-13 15:00:00","open":15.12,"high":15.28,"low":14.83,"amount":26690200,"amplitude":0.0298,"askPrice":14.88,"askSize":28,"bidPrice":14.87,"bidSize":31,"shortable":0,"etf":0,"ttmEps":0.6716,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1794792600000},"marketStatusCode":5,"adr":0,"adjPreClose":15.12,"symbolType":"stock","openAndCloseTimeList":[[1794533400000,1794540600000],[1794546000000,1794553200000]],"highLimit":16.63,"lowLimit":13.61,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":228218618,"isCdr":false,"pbRate":1.85,"roa":"--","peRate":22.141155,"roe":"5.89%","epsLYR":0.87,"committee":-0.017341,"marketValue":3394000000,"turnoverRate":0.0106,"status":1,"nextConnectDate":"根据港交所公布的数据,今日已停止北向交易,下一个交易日为北京时间 2026-11-16。","floatMarketCap":2506000000},"requestUrl":"/m/hq/s/003020","defaultTab":"news","newsList":[{"id":"2681854858","title":"立方制药(003020.SZ)子公司取得加替沙星滴眼液药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2681854858","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681854858?lang=zh_cn&edition=full","pubTime":"2026-11-06 17:47","pubTimestamp":1793958439,"startTime":"0","endTime":"0","summary":"智通财经APP讯,立方制药(003020.SZ)发布公告,近日,公司控股子公司合肥诺瑞特制药有限公司(以下简称“诺瑞特”)收到国家药品监督管理局核准签发的加替沙星滴眼液《药品注册证书》。据悉,加替沙星是一种环丙基氟喹诺酮类药物,为第四代喹诺酮类广谱抗菌药物。本次获批产品加替沙星滴眼液主要用于由敏感菌引起的急性细菌性结膜炎,该产品以日本千寿制药株式会社的未进口原研药品为参比制剂进行开发研究,为仿制境外上市但境内未上市原研药品的药品(注册分类为化药3类)。截至本公告日,国内企业除公司外,另有10家企业持有该产品药品批文。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1519754.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"立方制药(003020.SZ)子公司取得加替沙星滴眼液药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["003020","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679287286","title":"立方制药(003020.SZ)发布前三季度业绩,归母净利润1.09亿元,同比下降9.86%","url":"https://stock-news.laohu8.com/highlight/detail?id=2679287286","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679287286?lang=zh_cn&edition=full","pubTime":"2026-10-29 22:27","pubTimestamp":1793284073,"startTime":"0","endTime":"0","summary":"智通财经APP讯,立方制药(003020.SZ)发布2026年第三季度报告,公司前三季度实现营业收入9.86亿元,同比下降8.76%;归属于上市公司股东的净利润1.09亿元,同比下降9.86%;归属于上市公司股东的扣除非经常性损益的净利润7212.18万元,同比下降19.29%;基本每股收益0.4777元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1515584.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["003020"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679840586","title":"立方制药(003020)9月30日股东户数2.06万户,较上期增加36%","url":"https://stock-news.laohu8.com/highlight/detail?id=2679840586","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679840586?lang=zh_cn&edition=full","pubTime":"2026-10-29 19:09","pubTimestamp":1793272197,"startTime":"0","endTime":"0","summary":"证券之星消息,近日立方制药披露,截至2026年9月30日公司股东户数为2.06万户,较6月30日增加5462.0户,增幅为36.0%。在化学制药行业个股中,立方制药股东户数低于行业平均水平,截至9月30日,化学制药行业平均股东户数为3.95万户。从股价来看,2026年6月30日至2026年9月30日,立方制药区间涨幅为16.54%,在此期间股东户数增加5462.0户,增幅为36.0%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102900046082.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","003020"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675742532","title":"股市必读:立方制药新发布《关于收到原料药上市申请受理通知书的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2675742532","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675742532?lang=zh_cn&edition=full","pubTime":"2026-10-16 03:33","pubTimestamp":1792092788,"startTime":"0","endTime":"0","summary":"公司公告汇总关于收到原料药上市申请受理通知书的公告合肥立方制药股份有限公司近日收到国家药品监督管理局下发的盐酸米安色林原料药上市申请《受理通知书》。该原料药为仿制境内已上市药品所用化学原料药。本次受理标志着该品种进入注册审评阶段,对公司近期业绩无重大影响;若后续通过审评,将丰富公司原料药产品管线。产品获批时间及结果存在不确定性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101600004214.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","003020"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675301859","title":"立方制药(003020)10月15日主力资金净卖出49.87万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2675301859","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675301859?lang=zh_cn&edition=full","pubTime":"2026-10-15 15:29","pubTimestamp":1792049346,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2026年10月15日收盘,立方制药报收于16.31元,下跌0.31%,换手率1.57%,成交量2.65万手,成交额4330.31万元。10月15日的资金流向数据方面,主力资金净流出49.87万元,占总成交额1.15%,游资资金净流入344.78万元,占总成交额7.96%,散户资金净流出294.91万元,占总成交额6.81%。立方制药主营业务:药品制剂及原料药的研发、生产、销售,药品与医疗器械的批发、零售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101500020506.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","003020"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675328208","title":"立方制药(003020)披露收到盐酸米安色林原料药上市申请受理通知书,10月14日股价下跌1.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2675328208","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675328208?lang=zh_cn&edition=full","pubTime":"2026-10-14 22:34","pubTimestamp":1791988455,"startTime":"0","endTime":"0","summary":"截至2026年10月14日收盘,立方制药报收于16.36元,较前一交易日下跌1.74%,最新总市值为37.34亿元。该股当日开盘16.52元,最高16.64元,最低16.32元,成交额达3502.33万元,换手率为1.26%。近日,合肥立方制药股份有限公司收到国家药品监督管理局下发的盐酸米安色林原料药上市申请《受理通知书》。该品种属于仿制境内已上市药品所用的化学原料药。此次申请获受理,表示该品种进入注册审评阶段,对公司近期业绩无重大影响。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101400040154.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","003020"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675126337","title":"立方制药(003020.SZ):盐酸氯普鲁卡因原料药上市申请获得批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2675126337","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675126337?lang=zh_cn&edition=full","pubTime":"2026-10-13 17:26","pubTimestamp":1791883566,"startTime":"0","endTime":"0","summary":"智通财经APP讯,立方制药(003020.SZ)发布公告,近日,公司收到国家药品监督管理局下发的盐酸氯普鲁卡因《化学原料药上市申请批准通知书》。盐酸氯普鲁卡因是一种局部麻醉药,能够阻止神经末梢的钠离子通道,使神经冲动无法传递,从而使感觉神经末梢的传导阻断,产生局部麻醉作用,其制剂适用于局部浸润麻醉、周围神经阻滞麻醉、骶管和硬膜外麻醉。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1506510.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IPOS","003020","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669506734","title":"立方制药(003020)9月24日主力资金净买入123.50万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2669506734","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669506734?lang=zh_cn&edition=full","pubTime":"2026-09-24 15:36","pubTimestamp":1790235410,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2026年9月24日收盘,立方制药报收于16.99元,下跌4.28%,换手率2.09%,成交量3.53万手,成交额6096.3万元。9月24日的资金流向数据方面,主力资金净流入123.5万元,占总成交额2.03%,游资资金净流出490.2万元,占总成交额8.04%,散户资金净流入366.69万元,占总成交额6.02%。立方制药主营业务:药品制剂及原料药的研发、生产、销售,药品与医疗器械的批发、零售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092400022019.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","003020"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669438622","title":"股市必读:立方制药新发布《关于立方制药2026年第一次临时股东会的法律意见书》","url":"https://stock-news.laohu8.com/highlight/detail?id=2669438622","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669438622?lang=zh_cn&edition=full","pubTime":"2026-09-24 01:23","pubTimestamp":1790184189,"startTime":"0","endTime":"0","summary":"公司公告汇总关于立方制药2026年第一次临时股东会的法律意见书安徽天禾律师事务所对合肥立方制药股份有限公司2026年第一次临时股东会的召集、召开程序、出席会议人员资格、召集人资格、表决程序及表决结果进行了见证。安徽天禾律师事务所对本次会议出具法律意见,认为会议决议合法有效。关于完成独立董事补选的公告合肥立方制药股份有限公司于2026年9月4日召开第六届董事会第七次会议,提名潘立生先生为第六届董事会独立董事候选人。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092400001999.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["003020","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666590515","title":"股市必读:立方制药新发布《关于参加2026年安徽上市公司投资者网上集体接待日活动的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2666590515","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666590515?lang=zh_cn&edition=full","pubTime":"2026-09-11 01:49","pubTimestamp":1789062551,"startTime":"0","endTime":"0","summary":"截至2026年9月10日收盘,立方制药报收于16.93元,下跌3.15%,换手率1.99%,成交量3.35万手,成交额5726.16万元。公司公告汇总:立方制药将于2026年9月17日15:30–17:00参加安徽上市公司投资者网上集体接待日活动,通过“全景路演”平台与投资者就半年度业绩、发展战略等进行交流。活动将于2026年9月17日15:30–17:00通过网络远程方式举行,投资者可通过“全景路演”网站、微信公众号“全景财经”或下载全景路演APP参与。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091100002425.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","003020"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663104064","title":"股市必读:立方制药中报 - 第二季度单季净利润同比增长1.80%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663104064","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663104064?lang=zh_cn&edition=full","pubTime":"2026-08-31 06:54","pubTimestamp":1788130451,"startTime":"0","endTime":"0","summary":"当日关注点交易信息汇总:8月28日主力资金净流出655.24万元,占总成交额6.97%; 股本股东变化:截至2026年6月30日股东户数为1.52万户,较3月31日减少8.82%,户均持股升至1.5万股; 业绩披露要点:2026年第二季度单季度归母净利润5291.43万元,同比上升1.8%; 公司公告汇总:公司为控股子公司诺瑞特提供总额不超过11,000万元的连带责任保证担保,授信额度在已审批范围内内部调剂,担保总额未增加。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083100001711.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["003020"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663787048","title":"立方制药(003020)2026年中报简析:净利润同比下降2.24%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663787048","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663787048?lang=zh_cn&edition=full","pubTime":"2026-08-30 06:26","pubTimestamp":1788042403,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期立方制药发布2026年中报。根据财报显示,立方制药净利润同比下降2.24%。截至本报告期末,公司营业总收入6.84亿元,同比下降6.58%,归母净利润8820.51万元,同比下降2.24%。按单季度数据看,第二季度营业总收入3.27亿元,同比下降12.1%,第二季度归母净利润5291.43万元,同比上升1.8%。去年的净利率为10.53%,算上全部成本后,公司产品或服务的附加值一般。本文数据来源于立方制药2026年中报,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083000002891.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["003020"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662994210","title":"立方制药(003020)披露关于调剂银行授信额度暨为子公司提供担保的进展公告,8月28日股价下跌0.53%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662994210","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662994210?lang=zh_cn&edition=full","pubTime":"2026-08-28 22:18","pubTimestamp":1787926726,"startTime":"0","endTime":"0","summary":"截至2026年8月28日收盘,立方制药报收于18.65元,较前一交易日下跌0.53%,最新总市值为42.56亿元。近日,合肥立方制药股份有限公司发布关于调剂银行授信额度暨为子公司提供担保的进展公告。根据实际授信批复情况,对两家银行的授信额度进行内部调剂,兴业银行授信额度由6,000万元调整为2,000万元,浦发银行由5,000万元调整为9,000万元,担保总额未增加,仍在已审批额度内。公司累计对外担保额度为17,000万元,占2025年经审计净资产的9.40%,无逾期担保。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800054533.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","003020","161121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662062645","title":"图解立方制药中报:第二季度单季净利润同比增长1.80%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662062645","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662062645?lang=zh_cn&edition=full","pubTime":"2026-08-28 18:59","pubTimestamp":1787914764,"startTime":"0","endTime":"0","summary":"证券之星消息,立方制药2026年中报显示,上半年度公司主营收入6.84亿元,同比下降6.58%;归母净利润8820.51万元,同比下降2.24%;扣非净利润5425.8万元,同比下降18.07%;其中2026年第二季度,公司单季度主营收入3.27亿元,同比下降12.1%;单季度归母净利润5291.43万元,同比上升1.8%;单季度扣非净利润2074.77万元,同比下降40.07%;负债率24.28%,投资收益304.06万元,财务费用37.41万元,毛利率66.44%。财报数据概要请见下图:本文数据来源于立方制药2026年中报,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800044320.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["003020"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662306161","title":"立方制药(003020.SZ)发布半年度业绩,归母净利润8820.51万元,同比下降2.24%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662306161","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662306161?lang=zh_cn&edition=full","pubTime":"2026-08-28 18:21","pubTimestamp":1787912494,"startTime":"0","endTime":"0","summary":"智通财经APP讯,立方制药 发布2026年半年度报告,报告期内,公司实现营业收入6.84亿元,同比下降6.58%;实现归属于母公司所有者净利润8820.51万元,同比下降2.24%;实现归属于上市公司股东的扣除非经常性损益的净利润5425.8万元,同比下降18.07%;基本每股收益0.3865元。报告期,面对当前错综复杂的外部经营环境,公司紧紧围绕年度经营目标,坚持“稳增长、强拓展、优效率”的工作主线。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1488110.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["003020"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662066287","title":"立方制药(003020)6月30日股东户数1.52万户,较上期减少8.82%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662066287","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662066287?lang=zh_cn&edition=full","pubTime":"2026-08-28 17:50","pubTimestamp":1787910647,"startTime":"0","endTime":"0","summary":"证券之星消息,近日立方制药披露,截至2026年6月30日公司股东户数为1.52万户,较3月31日减少1468.0户,减幅为8.82%。在化学制药行业个股中,立方制药股东户数低于行业平均水平,截至6月30日,化学制药行业平均股东户数为3.67万户。从股价来看,2026年3月31日至2026年6月30日,立方制药区间跌幅为25.66%,在此期间股东户数减少1468.0户,减幅为8.82%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800041365.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","003020"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662736495","title":"立方制药(003020)披露收到盐酸曲唑酮原料药上市申请受理通知书,8月25日股价上涨6.63%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662736495","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662736495?lang=zh_cn&edition=full","pubTime":"2026-08-25 18:57","pubTimestamp":1787655432,"startTime":"0","endTime":"0","summary":"截至2026年8月25日收盘,立方制药报收于18.65元,较前一交易日上涨6.63%,最新总市值为42.56亿元。该股当日开盘17.29元,最高19.16元,最低17.13元,成交额达2.11亿元,换手率为6.85%。近日,合肥立方制药股份有限公司收到国家药品监督管理局下发的盐酸曲唑酮原料药上市申请《受理通知书》,申请事项为上市,受理号为CYHS2660565,登记号为Y20260000741。盐酸曲唑酮适用于抑郁症治疗,本次申请为仿制境内已上市药品所用的化学原料药。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082500040126.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["003020","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657641070","title":"立方制药(003020)披露产品中选第12批国家药品集采,8月7日股价上涨5.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2657641070","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657641070?lang=zh_cn&edition=full","pubTime":"2026-08-07 22:09","pubTimestamp":1786111748,"startTime":"0","endTime":"0","summary":"截至2026年8月7日收盘,立方制药报收于18.43元,较前一交易日上涨5.13%,最新总市值为42.06亿元。近日,合肥立方制药股份有限公司披露公告,其产品甲磺酸多沙唑嗪缓释片和美阿沙坦钾片拟中选第12批国家组织药品集中带量采购,并于2026年8月6日正式公布中选结果。甲磺酸多沙唑嗪缓释片2025年度销售收入为10,340.95万元,占公司当年营业收入的6.66%;美阿沙坦钾片于2026年5月19日获批上市,尚未产生销售收入。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080700040655.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","003020"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656305836","title":"股市必读:立方制药新发布《关于公司产品拟中选国家组织药品集中带量采购的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2656305836","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656305836?lang=zh_cn&edition=full","pubTime":"2026-08-04 01:25","pubTimestamp":1785777912,"startTime":"0","endTime":"0","summary":"公司公告汇总关于公司产品拟中选国家组织药品集中带量采购的公告合肥立方制药股份有限公司参与第12批国家组织药品集中带量采购,甲磺酸多沙唑嗪缓释片和美阿沙坦钾片拟中选。甲磺酸多沙唑嗪缓释片2025年度销售收入为10,340.95万元,占公司营业收入6.66%;美阿沙坦钾片于2026年5月19日获批上市,尚未产生销售收入。采购周期至2029年12月31日,中选结果公示无异议后将签订合同。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080400001239.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["003020","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656471913","title":"立方制药(003020.SZ):两款产品拟中选国家组织药品集中带量采购","url":"https://stock-news.laohu8.com/highlight/detail?id=2656471913","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656471913?lang=zh_cn&edition=full","pubTime":"2026-08-03 12:06","pubTimestamp":1785729996,"startTime":"0","endTime":"0","summary":"智通财经APP讯, 立方制药(003020.SZ)发布公告,近日,公司参与了国家组织药品集中带量采购(第12批)的申报。根据国家组织药品联合采购办公室于2026年7月31日发布的《第12批国家组织药品集中带量采购拟中选结果公示》显示,公司部分产品拟中选本次带量采购,相关产品为:甲磺酸多沙唑嗪缓释片、美阿沙坦钾片。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1475143.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0250","003020"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1794683501798,"stockEarnings":[{"period":"1week","weight":-0.0217},{"period":"1month","weight":-0.0911},{"period":"3month","weight":-0.2027},{"period":"6month","weight":-0.1665},{"period":"1year","weight":-0.4241},{"period":"ytd","weight":-0.2998}],"compareEarnings":[{"period":"1week","weight":-0.0041},{"period":"1month","weight":-0.0353},{"period":"3month","weight":-0.0746},{"period":"6month","weight":-0.1212},{"period":"1year","weight":-0.0981},{"period":"ytd","weight":-0.0843}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"合肥立方制药股份有限公司","boardCode":"AI0051","boardName":"批发业","stockholders":"179468人(较上一季度增加769.81%)","perCapita":"939股","listingDate":"2020-12-15","address":"安徽省合肥市蜀山区长江西路669号立方厂区","registeredCapital":"22821万元","survey":" 合肥立方制药股份有限公司的主营业务是药品制剂及原料药的研发、生产、销售,药品与医疗器械的批发、零售。公司的主要产品是精神麻醉药、独家现代中药。公司两次荣获“中国医药工业最具投资价值企业”称号,连续八年入选“中国化学制药工业企业综合实力百强”,获国家高新技术企业、安徽省专精特新企业50强、安徽省科学技术奖一等奖、皖美品牌示范企业等荣誉。","listedPrice":23.13},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"立方制药(003020)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供立方制药(003020)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"立方制药,003020,立方制药股票,立方制药股票老虎,立方制药股票老虎国际,立方制药行情,立方制药股票行情,立方制药股价,立方制药股市,立方制药股票价格,立方制药股票交易,立方制药股票购买,立方制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"立方制药(003020)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供立方制药(003020)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}